Drug
Insulin Glargine (HOE901 - U300)
Insulin Glargine (HOE901 - U300) is a pharmaceutical drug with 2 clinical trials. Historical success rate of 100.0%.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_3
1
50%
Ph phase_4
1
50%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution2 total trials
Phase 3Large-scale testing
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Active(1)
Completed(1)
Detailed Status
Not yet recruiting1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 31 (50.0%)
Phase 41 (50.0%)
Trials by Status
not_yet_recruiting150%
completed150%
Recent Activity
0 active trials
Showing 2 of 2
not_yet_recruitingphase_4
Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes
NCT07173712
completedphase_3
Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications
NCT02320721
Clinical Trials (2)
Showing 2 of 2 trials
NCT07173712Phase 4
Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes
NCT02320721Phase 3
Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2